BridgeBio Oncology Therapeutics, Inc. (BBOT)

NASDAQ: BBOT · USD

$2.82

+0.13 (+4.8%)· Recorded snapshot

Market cap	226.1M
Net income (ttm)	-182.1M
EPS (ttm)	-$2.56
Shares out	80.2M
Volume	413,194
Beta	0.65

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -182.1M
EPS (ttm): -$2.56
Market cap: 226.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantener

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-81.9

P25 -113.8P50 -46.5P75 -0.9

ROIC-55.3

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All BBOT indicators

Market & fundamental data

Available fields

161

Groups with data

Currency

USD

Showing 161 of 161 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001869105
Company name	BridgeBio Oncology Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	107924102
Earnings date	2026-11-11
Earnings time	amc
Employees	88
Employees change	26
Employees growth	41.94%
Enterprise value	$-115.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US1079241022
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$226.1M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	No
Price	$2.82
Price currency	USD
Sector	Healthcare
Stock price date	2026-10-28
Symbol	BBOT
U.S. state	California
Website	https://bbotx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-90.75%
FCF / EV yield	120.34%
FCF yield	-70.28%
P/B ratio	0.67x
Price / tangible book value	0.67x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-2.1M
ROA	-47.1%
ROCE	-61.2%
ROE	-81.92%
ROIC	-55.27%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-284,000
Depreciation and amortization	$307,000
EBIT	$-199M
EBITDA	$-198.6M
EPS	$-2.56
FCF per share	$-1.89
Financing cash flow	$365.2M
Free cash flow	$-151.6M
Free cash flow minus SBC	$-167M
Investing cash flow	$-191.4M
Net cash flow	$22.5M
Net income	$-182.1M
Operating cash flow minus SBC	$-166.7M
Operating income	$-199M
Stock-based compensation	$15.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.03
Debt / equity	0.01
Long-term assets	$134.3M
Long-term liabilities	$2M
Net cash (debt)	$341.6M
Net cash / market cap	158.4%
Net cash growth	165.72%
Net debt / equity	-1.06
Piotroski F-Score	1
Property, plant and equipment	$3M
Shareholders' equity	$323.1M
Tangible book value	$323.1M
Tangible book value per share	$4.03
Total assets	$376.7M
Total cash	$225.7M
Total debt	$2.5M
Total liabilities	$53.6M
WACC	7.75%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$242.4M
Current liabilities	$51.6M
Current ratio	4.69
Net working capital	$-34.4M
Quick ratio	4.38
Working capital	$190.7M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-12,503.2%
Dividend yield	0%
Shareholder yield	-12,503.2%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$7.42
1D price change	4.83%
1M price change	-29.62%
1M total return	-29.62%
1W price change	2.21%
1W total return	2.21%
1Y price change	-75.42%
1Y return CAGR	-75.44%
1Y total return	-75.42%
20-day SMA	$3.09
200-day SMA	$8.23
3M price change	-68.23%
3M total return	-68.23%
50-day SMA	$5.27
50-day SMA vs 200-day SMA	50under200
52-week high	$14.87
52-week high date	2025-12-08
52-week low	$2.51
52-week low date	2026-10-27
6M price change	-68.37%
6M total return	-68.37%
All-time high	$14.87
All-time high date	2025-12-08
All-time low	$2.51
All-time low date	2026-10-27
Average true range (ATR)	$0.26
Average volume	637.6K
Beta (1Y)	1.35
Beta (2Y)	0.5
Beta (5Y)	0.65
Change from 52-week high	-81.04%
Change from 52-week low	12.35%
Change from all-time high	-81.3%
Change from all-time low	10.76%
Change from open	5.22%
Day's gap	-0.37%
Dollar volume	$1.2M
High price	$2.85
Low price	$2.68
Monthly RSI	23.69
Open price	$2.68
Position in 52-week range	82.35%
Premarket change	-1.12%
Premarket close	$2.69
Premarket price	$2.66
Previous close	$2.69
Price vs 150-day SMA	-62.51%
Price vs 20-day SMA	-10.12%
Price vs 200-day SMA	-66.2%
Price vs 50-day SMA	-47.23%
Relative volume	0.65
RSI	25.78
Sharpe ratio	-1.71
Sortino ratio	-2.09
Volume	413.2K
Weekly RSI	24.98
YTD price change	-77.8%
YTD total return	-77.8%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	35.8M
Float percentage	44.67%
Shares change (QoQ)	0.03%
Shares change (YoY)	12,503.2%
Shares held by insiders	0.02%
Shares held by institutions	45.55%
Shares outstanding	80.2M
Short % of float	9.42%
Short % of shares	4.21%
Short ratio	4.7 days

Deeper analysis on BBOT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BBOT report

Is a complete BBOT research report available?

No complete published report is available for BridgeBio Oncology Therapeutics, Inc. (BBOT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BridgeBio Oncology Therapeutics, Inc. (BBOT)

Price

Financial snapshot

Fair-value bridge

Latest news · BBOT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BBOT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BBOT

Frequently asked questions